Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Mobile Health Intervention to Improve Exercise in Pediatric PH
Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations.
- Trial name
- MhOVE-PPH (NCT06549452)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Disease, Pulmonary Hypertension
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
- Trial name
- NCT01730092
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Artery Hypertension
Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?
Patients with hemolytic disorders (e.g. sickle cell anemia or thalassemia) are known to develop pulmonary hypertension. Hemolysis is where red blood cells are destroyed and their contents released into the circulation.
- Trial name
- NCT00502398
- Testing
- Blood test
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Pulmonary Hypertension
Remote Exercise Program Delivery Using a Mobile Application for Pulmonary Arterial Hypertension
This study will determine the feasibility of a mobile application-based home exercise rehabilitation program for patients with pulmonary hypertension.
- Trial name
- REVAMP (NCT04559516)
- Testing
- Exercise Intervention, Standard Care
- Where
- Canada
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
Positioning Imatinib for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare condition in which a narrowing of blood vessels carrying blood through the lungs puts an increased work load on the heart; it has to work harder to pump blood through the lungs.
- Trial name
- PIPAH (NCT04416750)
- Testing
- Imatinib Mesylate
- Where
- 4 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension (PAH)
Information Sources in Pulmonary Hypertension
Pulmonary hypertension is a serious disease that affects patients' health, daily life, and emotional well-being. Many patients and their caregivers actively look for information to better understand the condition and its…
- Trial name
- inPHorma (NCT07207525)
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension (PAH)
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by structural changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and elevated pulmonary arterial pressure and…
- Trial name
- SOFAPI (NCT07357974)
- Testing
- [68Ga]Ga-FAPI PET/CT, [68Ga]Ga-MAA PET/CT
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Brest
Blood Pressure, Hypertension
Onco-primary Care Networking to Support TEAM-based Care
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- ONE TEAM (NCT04258813)
- Testing
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- Duke University
Pulmonary Arterial Hypertension, Healthy
Right Ventricular Metabolism in Pulmonary Arterial Hypertension
The purpose of this study is to use non-invasive imaging to determine the metabolic phenotype of the right ventricle in patients with pulmonary arterial hypertension across a spectrum of disease severity.
- Trial name
- NCT02763735
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Effects of DHEA in Pulmonary Hypertension
The goal of this crossover trial is to determine whether the study drug dehydroepiandrosterone (DHEA) improves right ventricular longitudinal strain measured by cardiac magnetic resonance imaging at 18 weeks AND 40 weeks compared…
- Trial name
- EDIPHY (NCT03648385)
- Testing
- DHEA tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhode Island Hospital
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH)
Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
- Conditions
- Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), Home Monitoring Follow-up
- Trial name
- Nor-SScCare (NCT06865118)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially life-threatening disease characterized by pulmonary vascular remodeling, increased pulmonary vascular resistance, and right ventricular dysfunction.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Trial name
- ACTION (NCT07013149)
- Testing
- Switch from Ambrisentan to Bosentan, Maintenance of Ambrisentan Therapy
- Where
- Brazil
- Volunteers
- 183 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
Hemodynamic Response After Six Months of Sildenafil
The purpose of this study is to determine the clinical, functional and hemodynamic response after six months of sildenafil 50 mg TID in patients with pulmonary arterial hypertension.
- Trial name
- NCT00483626
- Testing
- oral sildenafil
- Where
- Chile
- Volunteers
- 27 people
- Sponsor
- University of Chile
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
High Altitude Effects, High Altitude
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in patients with pulmonary arterial…
- Conditions
- High Altitude Effects, High Altitude, Pulmonary Vascular Disease, Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07801859
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Exercise-induced Pulmonary Arterial Hypertension
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH).
- Trial name
- EiPAH (NCT01338636)
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension WHO Group I
Imaging Control Study, 3D Echo, MR and RHC.
The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional echocardiography in order to…
- Trial name
- PARIS (NCT02198456)
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Regina Steringer-Mascherbauer
Pulmonary Arterial Hypertension, Congenital Heart Disease
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is common in patients with congenital heart disease.
- Conditions
- Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
- Trial name
- NCT01319045
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Los Angeles